IP Library Granted Patent US 10,712,277
Granted Patent B2
US 10,712,277 · App. 12/932,912 · Granted Jul 14, 2020

Raman imaging devices and methods of molecular imaging

Inventors: Sanjiv Sam Gambhir (Portola Valley, CA); Cristina Zavaleta (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
G01N21/658A61B5/0071A61B5/0075A61K49/00A61K49/0002A61K49/0065A61K49/0093A61K51/1244B82Y5/00B82Y15/00B82Y30/00A61B5/0073A61B5/0084A61B5/0088A61B5/416
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,712,277
App. No.
12/932,912
Granted
Jul 14, 2020
Kind
B2
Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to Raman imaging devices (e.g., Raman endoscope probes), methods of using Raman agents and Raman imaging devices to image or detect a signal, and the like.

Claims (36)

1. A method of imaging, comprising:

administering at least two types of Raman agents to a subject, wherein at least one of the two types of Raman agents has a specific affinity for a specific target;

introducing a Raman imaging device into the subject;

positioning the Raman imaging device adjacent the specific target inside the subject;

exposing the specific target inside the subject to a light beam from the Raman imaging device, wherein the light beam is scattered by the first type of Raman agent that associated with the specific target, wherein the light beam that is scattered is referred to as a Raman scattered light energy; and

detecting the Raman scattered light inside the subject using the Raman imaging device, using the Raman scattered light energy to form an image; and

analyzing the scattered light to determine the type of Raman agent, wherein the type of Raman agent determines the specific target detected,

wherein one of the at least two types of Raman agent is not target-specific, and wherein the method further comprises analyzing the scattered light to determine the ratio of the specific binding Raman agent to non-specific binding Raman agent, wherein the ratio provides an estimate of the bound Raman agents.

2. The method of claim 1 , wherein the Raman agent is selected from the group consisting of: a Raman nanoparticle and a Raman compound.

3. The method of claim 1 , wherein the specific target is selected from the group consisting of: cancer, tumor, precancerous cells or tissue, atherosclerosis, and fibrosis.

4. The method of claim 1 , wherein introducing the Raman imaging device includes introducing into the subject the Raman imaging device to an anatomical region of the subject, wherein the anatomical region of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

5. The method of claim 4 , further comprising, mapping of at least a portion of the subject using the Raman scattered light, wherein mapping includes collecting Raman scattered light and correlating the Raman scattered light to a position in at least a portion of the inside of the subject, wherein the portion of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

6. The method of claim 1 , wherein administering includes administering, locally to the colon, a gold nanoparticle Raman agent having a targeting agent specific for a dysplastic flat lesion in the colon, wherein the specific target is a dysplastic flat lesion, and wherein introducing includes introducing into the colon.

7. The method of claim 1 , wherein administering includes administering, locally to the colon, a polyethylene glycol (PEG)-ylated Raman active silica-gold nanoparticle Raman agent having a targeting agent specific for colorectal cancer, wherein the specific target is a colorectal cancer, and wherein introducing includes introducing into the colon.

8. A method of imaging, comprising:

administering a plurality of types of Raman agents to a subject, wherein at least two types of Raman agents have a specific affinity for a different target;

positioning inside the subject a Raman imaging device adjacent an area that includes one or more of the different targets;

exposing the area inside the subject to a light beam from the Raman imaging device, wherein if one or more of the plurality of Raman agents is present, the light beam is scattered, wherein the light beam that is scattered is referred to as a Raman scattered light energy, wherein each different type of Raman agent has a detectably different Raman scattered light energy;

detecting inside the subject the Raman scattered light using the Raman imaging device; and

analyzing the scattered light to determine the type of Raman agent, wherein the type of Raman agent determines a target detected,

wherein at least one of the plurality of Raman agents is not target-specific, and wherein the method further comprises analyzing the scattered light to determine the ratio of the specific binding Raman agent to non-specific binding Raman agent, wherein the ratio provides an estimate of the bound Raman agents.

9. The method of claim 8 , wherein each target is selected from the group consisting of: cancer, tumor, precancerous cells or tissue, atherosclerosis, fibrosis, and a combination thereof.

10. The method of claim 8 , wherein introducing the Raman imaging device includes introducing inside the subject the Raman imaging device to an anatomical region of the subject, wherein the anatomical region of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

11. The method of claim 10 , further comprising, mapping of at least a portion of the subject using the Raman scattered light, wherein mapping includes collecting Raman scattered light and correlating the Raman scattered light to a position in at least a portion of the inside of the subject, wherein the portion of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

12. A method of imaging, comprising:

administering at least two types of Raman agents to a subject, wherein at least one of the two types of the Raman agents has a specific affinity for a specific target;

introducing a Raman imaging device into the subject;

positioning the Raman imaging device adjacent the specific target inside the subject;

exposing the specific target inside the subject to a light beam from the Raman imaging device, wherein the light beam is scattered by the first type of Raman agent that associated with the specific target, wherein the light beam that is scattered is referred to as a Raman scattered light energy;

detecting the Raman scattered light inside the subject using the Raman imaging device, using the Raman scattered light energy to form an image; and

wherein administering includes administering, locally to the colon, a gold nanoparticle Raman agent having a targeting agent specific for a dysplastic flat lesion in the colon, wherein the specific target is a dysplastic flat lesion, and wherein introducing includes introducing into the colon; and

analyzing the scattered light to determine the type of Raman agent, wherein the type of Raman agent determines the specific target detected,

wherein one of the at least two types of Raman agent is not target-specific, and wherein the method further comprises analyzing the scattered light to determine the ratio of the specific binding Raman agent to non-specific binding Raman agent, wherein the ratio provides an estimate of the bound Raman agents.

13. The method of claim 12 , wherein administering includes administering, locally to the colon, a polyethylene glycol (PEG)-ylated Raman active silica-gold nanoparticle Raman agent having a targeting agent specific for colorectal cancer, wherein the specific target is a colorectal cancer, and wherein introducing includes introducing into the colon.

14. The method of claim 12 , wherein introducing the Raman imaging device includes introducing into the subject the Raman imaging device to an anatomical region of the subject, wherein the anatomical region of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

15. The method of claim 14 , further comprising, mapping of at least a portion of the subject using the Raman scattered light, wherein mapping includes collecting Raman scattered light and correlating the Raman scattered light to a position in at least a portion of the inside of the subject, wherein the portion of the subject is selected from the group consisting of: cervix, bladder, bronchioles, esophagus, stomach, colon, and rectum.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2011
From: GAMBHIR, SANJIV SAM; ZAVALETA, CRISTINA
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 027094/0145 →
CONFIRMATORY LICENSE Recorded Jun 8, 2011
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026406/0357 →
Continuity (3)
Continuation In Part 12598780
Provisional Application 60927574 · May 4, 2007
Related Publication 20110230760A1 · Sep 22, 2011